Sign in
PSTX Stock Price, Chart, Stats & News
Poseida Therapeutics, Inc.
Save
925.93M
Market cap
–
Current P/E
–
Forward P/E
PSTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -142.29% |
Operating margin | -200.15% |
Pretax margin | -190.60% |
Net margin | -190.76% |
Effective tax rate | -0.09% |
ROA | -45.07% |
ROE | -84.75% |
D/E | 0.82x |
Interest coverage ratio | -14.94x |
PSTX valuation
P/E | – |
P/S | 14.31x |
P/B | 8.26x |
P/CF | -9.30x |
P/FCF | -9.72x |
P/OCF | -9.30x |
PEG | -0.15x |
EV multiple | -8.12x |
About
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC).
Similar securities
Based on sector and market capitalization
Report issue